Continuous Glucose Monitoring Device
Continuous Glucose Monitoring for Diabetes
This trial will test whether or not systematic continuous glucose monitoring is an effective treatment option for patients with diabetes who are receiving care in a hospital setting.
Fish Oil for Diabetic Neuropathy
This trial is testing whether fish oil supplements can help people with type 2 diabetes who have nerve damage. The study aims to see if fish oil can repair damaged nerves and improve their function. If successful, this could provide a new treatment option for diabetic nerve damage.
Popular Filters
Trials for Type 2 Diabetes Patients
Potassium Channel Opener
Diazoxide for Type 2 Diabetes
This trial is testing diazoxide, a drug that activates parts of the brain, on people with type 2 diabetes. The goal is to see if it can help reduce the amount of glucose produced by the liver. By doing so, it may help manage high blood sugar levels in these patients. Diazoxide has been shown to improve blood sugar levels, help with weight loss, and affect certain genes in animal studies.
Guanylate Cyclase-C Agonist
Linaclotide for Chronic Constipation in Type 2 Diabetes
This trial has two phases. In the first phase, patients are randomly assigned to receive either the active drug or a placebo for 14 days. In the second phase, the order is reversed. There is a 2-week break in between phases during which patients do not receive any medication. The trial is closely monitored for safety.
Procedure
Surgical vs. Lifestyle Interventions for Type 2 Diabetes
This trial is being done to compare the effectiveness of two types of bariatric surgery against an intensive lifestyle intervention in promoting weight loss and improvements in Type 2 diabetes in moderately obese patients.
Trials for Type 1 Diabetes Patients
Monoclonal Antibodies
Ustekinumab for Type 1 Diabetes
This trial tests Ustekinumab, a drug used for psoriasis, in adults aged 18-35 with recent-onset type 1 diabetes. The drug aims to protect and regenerate insulin-producing cells by blocking harmful immune cells. This could reduce the need for insulin injections.
Guanylate Cyclase-C Agonist
Linaclotide for Chronic Constipation in Type 2 Diabetes
This trial has two phases. In the first phase, patients are randomly assigned to receive either the active drug or a placebo for 14 days. In the second phase, the order is reversed. There is a 2-week break in between phases during which patients do not receive any medication. The trial is closely monitored for safety.
Phase 3 Trials
Monoclonal Antibodies
Ustekinumab for Type 1 Diabetes
This trial tests Ustekinumab, a drug used for psoriasis, in adults aged 18-35 with recent-onset type 1 diabetes. The drug aims to protect and regenerate insulin-producing cells by blocking harmful immune cells. This could reduce the need for insulin injections.
Pulsed Acoustic Cellular Expression Device
Sound Wave Therapy for Diabetic Foot Ulcers
This trial is testing whether a sound wave device can help heal diabetic foot ulcers. The device has not been approved for this use, so it is considered investigational. The trial will compare the device to a sham device to see if it is more effective.
Procedure
Coronary Artery Bypass Graft +1 More for Cardiovascular Disease
The purpose of this study is to compare 5-year mortality rates in diabetic individuals with multivessel coronary artery disease (CAD) who undergo either coronary artery bypass grafting (CABG) surgery or percutaneous coronary stenting.
Biguanides
Lifestyle Changes + Metformin for Diabetes Prevention
This trial looks at the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population. Lifestyle reduced diabetes onset by 58% and metformin reduced diabetes onset by 31%.
Amylin Analog
Pramlintide for Type 2 Diabetes
The hypothesis of the study is that those obese patients with type 2 diabetes mellitus who do not respond to the FDA approved dose of 120 mcg of pramlintide (Symlin®) 3 times daily with expected glucose control require higher than FDA approved dosage. The primary objective of the study is to determine whether higher doses of pramlintide (Symlin®) in patients with type 2 diabetes mellitus control glucose better than the FDA approved dose of 120 mcg three times daily. The secondary objectives include proving whether higher dose pramlintide (Symlin®) is more efficacious in causing weight loss and reduction in waist circumference than standard dose pramlintide (Symlin®),to determine whether blood levels of certain hormones correlate with need for higher dose therapy,and to determine whether or not the rate of common adverse effects exceeds the maximum FDA approved pramlintide (Symlin®) dose of 120 mcg three times daily.
Trials With No Placebo
Procedure
Surgical vs. Lifestyle Interventions for Type 2 Diabetes
This trial is being done to compare the effectiveness of two types of bariatric surgery against an intensive lifestyle intervention in promoting weight loss and improvements in Type 2 diabetes in moderately obese patients.
View More Related Trials
Frequently Asked Questions
Introduction to gestational diabetes
What are the top hospitals conducting gestational diabetes research?
Gestational diabetes, a temporary form of diabetes that occurs during pregnancy, is an area of ongoing research and clinical trials in some top hospitals across the United States. In Minneapolis, the University of Minnesota leads the way with three active trials focused on gestational diabetes. This condition affects pregnant women by causing high blood sugar levels and can have significant health implications for both mother and baby. Similarly, Albert Einstein College of Medicine in the Bronx also has three current trials dedicated to studying gestational diabetes. By understanding this condition better, researchers aim to develop effective prevention strategies and treatment options. Further contributing to these efforts is Brigham and Women's Hospital in Boston with two active trials specifically targeting gestational diabetes. This hospital emphasizes patient care alongside cutting-edge research to improve outcomes for expectant mothers diagnosed with this condition.
Meanwhile, Columbia University Irving Medical Center in New york also recognizes the importance of investigating gestational diabetes through their two ongoing clinical trials that focus on better understanding its causes and exploring potential interventions or therapies. Lastly, Wake Forest University Health Sciences located in Winston-Salem joins these prestigious institutions as they conduct two active gestational diabetes trials aimed at improving management techniques for pregnant individuals affected by this metabolic disorder.
These hospitals' dedication to combating gestational diabetes underscores the urgent need for advancements in understanding this unique form of diabetes experienced during pregnancy. Such research not only benefits expecting mothers but also holds promise for future generations by equipping healthcare providers with crucial knowledge required to provide optimal care throughout pregnancy journeys
Which are the best cities for gestational diabetes clinical trials?
When it comes to gestational diabetes clinical trials, several cities stand out as hubs of research and development. Aurora, Colorado leads the pack with 9 active trials investigating treatments like Semaglutide, Tirzepatide Dose 2, and Treatment order 1. Following closely behind is Boston, Massachusetts with 8 ongoing studies focused on interventions such as Alert-based computerized decision support and Investigational Product - MIB 626. Los Angeles, California also makes its mark with 7 active trials examining treatment options including Semaglutide and Tirzepatide Dose 2. These cities provide individuals affected by gestational diabetes access to cutting-edge clinical trials that pave the way for advancements in care and improved outcomes.
Which are the top treatments for gestational diabetes being explored in clinical trials?
Clinical trials are currently investigating several promising treatments for gestational diabetes. One of the leading contenders is metformin, a widely used medication that has shown positive results in managing blood sugar levels during pregnancy. Another potential option being explored is glyburide, which has demonstrated efficacy in controlling gestational diabetes and reducing the need for insulin therapy. Additionally, researchers are studying the effects of dietary interventions and exercise programs as alternative approaches to managing this condition. These ongoing trials aim to provide effective strategies for treating gestational diabetes and improving outcomes for both mothers and babies.
What are the most recent clinical trials for gestational diabetes?
Recent clinical trials offer hope for managing gestational diabetes, a condition that affects pregnant women. One notable trial is examining the efficacy of Ritlecitinib as a potential treatment option, with promising results expected in Phase 2. Another study focuses on the benefits of Fish Oil Concentrate capsules, exploring their impact on gestational diabetes in both Phase 1 and Phase 2 trials. Additionally, researchers are investigating the effects of Active THC and its potential role in managing gestational diabetes through a Phase 1 trial. Furthermore, the GOLO for Life® Plan (G4LP) combined with Release Supplement is being studied in Phase 2 to evaluate its effectiveness for individuals dealing with this condition. Lastly, an investigational product called MIB 626 is undergoing evaluation during a Phase 2 trial to assess its impact on gestational diabetes management. These trials provide valuable insights into new possibilities for addressing gestational diabetes and improving outcomes for affected mothers-to-be.
What gestational diabetes clinical trials were recently completed?
Recently completed clinical trials have focused on advancing our understanding and treatment of gestational diabetes. Notably, a trial investigating the efficacy of Interventional Glycemia in Pregnant Women with Gestational Diabetes Mellitus concluded in July 2021. In addition, a study evaluating the effects of Omega-3 fatty acid supplementation on insulin resistance in women with gestational diabetes was successfully completed in October 2020. These recent advancements contribute to ongoing efforts to improve outcomes for mothers and babies affected by gestational diabetes, highlighting the commitment of researchers to address this important health concern during pregnancy.